Papillomavirus Infections Clinical Trials Database - Free Access to 28 Studies
Access comprehensive clinical trial information for Papillomavirus Infections through Pure Global AI's free database. This collection includes 28 clinical trials across multiple phases including Phase 3, N/A, Phase 1. Currently, 8 trials are actively recruiting participants.
Research for Papillomavirus Infections is being conducted in China, United States of America, Canada,United States of America and 7+ other countries. Leading sponsors include Merck Sharp & Dohme LLC and University of Washington. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Clinical Effectiveness of PAPILOCAREĀ® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
The KEN SHE Study on HPV-vaccine Efficacy
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
PApillomavirus in REnal Transplant Patient
GARDASILā¢ Post Marketing Surveillance in the Philippines (V501-077)
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
GARDASILā¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Self-collected Swabs for HPV Testing in 18-24 Year Old Women
A Study of V503 Vaccine Given Concomitantly With REPEVAXā¢ in 11 to 15 Year Olds (V503-007)
HPV Infections in Older Women
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
Pure Global AI provides free access to 28 clinical trials studying Papillomavirus Infections, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Merck Sharp & Dohme LLC, University of Washington, Merck Sharp & Dohme Corp., among others.